This is a preview of subscription content, log in via an institution to check access.
Notes
Canadian dollars (2012 values)
Reference
Prica A, et al. Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: A cost-effectiveness analysis. Cancer : 15 Apr 2015. Available from: URL: http://dx.doi.org/10.1002/cncr.29372
Rights and permissions
About this article
Cite this article
Rituximab induction looks good in asymptomatic follicular lymphoma. PharmacoEcon Outcomes News 727, 28 (2015). https://doi.org/10.1007/s40274-015-2112-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-015-2112-z